Individuals diagnosed with major depression often are found to have reduced volume within their hippocampus. The hippocampus is a small region of the brain that is responsible for regulating various memory and spatial navigation functions. It is also believed to play a pivotal role in the regulation of mood. Modern day antidepressants such as SSRIs …
NRX-1074 is a new antidepressant under development by the biotech company Naurex. It is this same company that has already been granted “fast track” status by the FDA for their intravenous antidepressant GLYX-13 – which shows significant promise. Naurex’s private stock has been steadily rising due to emergence of preliminary evidence suggesting that both of …
ALKS-5461 is a new drug that is being developed by the company Alkermes as an alternative to SSRI’s for the treatment of depression. ALKS-5461 (its trial name) is a combination of both buprenorphine (suboxone) and samidorphan, and is regarded as a non-addictive opioid modulator and antidepressant. It is currently being developed specifically as an antidepressant …